Kornimate/medical-research-clean huggingface dataset:
a study of the functional magnetic resonance imaging response to leptin and pramlintide

Conditions: Obesity

Summary: the purpose of this study is to identify how certain parts of the brain that help control body weight respond to an infusion of hormones called leptin and amylin.

following an overnight fast, subjects will undergo fmri measurements of the hypothalamus, brainstem and whole brain during an infusion of either normal saline, pramlintide, leptin, or the combination leptin and pramlintide.

Eligibility criteria:
inclusion criteria: * age 18 year to 45 years of age * mi 18 to 25 kg/m2 or ≥ 30 kg/m2 * at maximal lifetime weight * weight stable for at least 3 months exclusion criteria: * those with a major medical illness or who require prescription medication, including: cancer, coronary artery disease, hypertension, and diabetes. * subjects taking psychiatric or centrally-acting (cns) medications or who are diagnosed with a psychiatric or neurological illness, including: * depression * anorexia * bulimia * seizure disorder. * exercise \> 30 minutes, 3 times a week * alcohol consumption \> 2 drinks / day * weight \> 350 lbs (159 kg) (weight limit for mr machine) * illicit drug use * pregnancy * extreme dietary habits as determined by a gcrc nutritionist: very high or low dietary carbohydrate or fat intakes * those with a contraindication to exposure to strong magnetic fields: presence of metal in the body such as body piercing, shrapnel, cardiac pacemakers or aneurysm clips * those with claustrophobia * anaphylaxis and known hypersensitivity to e. coli-derived proteins * allergies or contraindications to metreleptin or pramlintide * renal or hepatic impairment * women who are lactating * tobacco use
green tea confections for managing postprandial hyperglycemia-induced vascular endothelial dysfunction

Conditions: Hyperglycemia; Cardiovascular Disease

Summary: the objective of this study is to formulate and validate a green tea confection (i.e. "gummy" candy) as a strategy to attenuate postprandial hyperglycemia-induced impairments in vascular function. the central hypothesis is that a green tea confection will protect against vascular endothelial dysfunction by suppressing postprandial hyperglycemia. the central hypothesis of this application will be assessed by developing a green tea-containing confection, examining its physiochemical properties and its inhibition of starch digestion, and then validating its vasoprotective activities in healthy humans by assessing its blood glucose-regulating activities.

the study involves validating a green tea confection (i.e. "gummy" candy) as a dietary strategy to attenuate postprandial hyperglycemia-induced impairments in vascular function. the central hypothesis is that a green tea confection will protect against vascular endothelial dysfunction by suppressing postprandial hyperglycemia. the central hypothesis of this application will be assessed by providing research participants 75 grams of carbohydrate in the form of a confection that contains no green tea concentrate or green tea concentrate at a level equivalent to approximately 3 cups of freshly brewed tea. blood glucose and brachial artery flow-mediated dilation will be assessed at regular intervals during the 3 hour postprandial period to define the extent to which green tea attenuates postprandial increases in blood glucose and decreases in vascular function that otherwise occur in a hyperglycemia-dependent manner.

Eligibility criteria:
inclusion criteria: * plasma glucose \<100 mg/dl * plasma total cholesterol \<200 mg/dl * plasma triglycerides \<140 mg/dl * blood pressure \<140/90 * non-dietary supplement user for \>2 months * no use of medications known to affect carbohydrate metabolism, * nonsmoker / never smoker * no history of cardiovascular disease or gastrointestinal disorders exclusion criteria: * allergies or aversions to green tea and/or corn starch, * excessive alcohol consumption (\>3 drinks/d), * \>5 h/wk of aerobic activity

Keywords: green tea catechins vascular endothelial function postprandial hyperglycemia oxidative stress
improving prenatal parental counseling in cases of sacrococcygeal teratoma

Conditions: Sacrococcygeal Teratoma

Summary: sacrococcygeal teratoma (sct) is the most common fetal and neonatal tumor. however, predicting factors of evolution, sequelae and relapse are still unreliable because of small-cohort studies. this study aims at identifying prenatal and postnatal prognostic factors of evolution of sct during pregnancy, of postnatal relapse, and of medium and long-term sequelae (urinary, digestive, esthetic, psychologic) in order to improve parental counseling when the diagnosis of sct is made during pregnancy.

sacrococcygeal teratoma (sct) is the most common fetal and neonatal tumor. although mostly benign, sct can lead to perinatal mortality and long-term sequelae. three main risks occur throughout the evolution of sct: 1. a perinatal life-threatening risk related to the importance of vascularization since sct can lead to a true arteriovenous fistula with the risk of cardiac failure 2. a risk of benign or malignant tumor recurrence 3. a risk of medium and long-term sequelae, mostly urinary and/or digestive disorders but also aesthetic and psychologic. in most cases, a prenatal diagnosis is made for which physicians are expected to give a prognosis and counsel parents about medium and long-term complications. however, there is no robust data to date correlating prenatal and postnatal features to prenatal and postnatal evolution of the tumor. the situation is all the more delicate as the information given by the physician can lead to the parent's will to terminate the pregnancy. this retrospective multicentric study aims at identifying prenatal and postnatal prognostic factors of sct evolution during pregnancy, the occurrence of postnatal relapse after surgical excision, and medium- and long-term sequelae. the primary goal of this study is to improve prenatal parental counseling when the diagnosis of sct is made.

Eligibility criteria:
inclusion criteria: * fetuses and infants (\< 1 year) diagnosed with benign sacrococcygeal teratoma * cared for between january 2007 and december 2017 in the participating centers exclusion criteria: * currarino syndrome * other benign sacrococcygeal teratoma discovered after 1 year old or malignant sacrococcygeal tumors

Keywords: sacrococcygeal teratoma prenatal diagnosis prenatal counseling prognostic factors neonatal tumor
evaluation of the german short-form qualiveen questionnaire

Conditions: Spinal Cord Injuries

Summary: two questionnaires (qualiveen full version and qualiveen short-form (sf)), the project information and the consent form will be sent to individuals who are scheduled for an annual control at the urological out-patient clinic of the swiss paraplegic centre and who fulfill the inclusion criteria. the patients will be asked to complete the two questionnaires and to bring the completed questionnaires and the signed consent form to the annual control at the swiss paraplegic centre. participants who have consented and completed the two questionnaires will receive the two questionnaires a second time 14 days later. the primary objective of this project is to validate the german version of the sf qualiveen questionnaire. the secondary objective is to evaluate the measurement properties of the german sf qualiveen questionnaire in comparison with the full version.


Eligibility criteria:
inclusion criteria: * chronic (≥ 12 months) neurogenic lower urinary tract dysfunction due to sci * age ≥ 18 years exclusion criteria: * no informed consent as documented by signature * history of concomitant neurological or psychological illness * history of cognitive impairment * insufficient german language skills
a population-based, multicenter cohort study of combined screening for gastrointestinal tumors

Conditions: Digestive Disease

Summary: to establish combined gastroenteroscopy screening and follow-up management for gastrointestinal tumors, explore and evaluate the feasibility and health economic benefits of combined screening for esophagus, stomach and colorectal cancer

group one: the screening population will undergo gastroscopy, colonoscopy, fecal occult blood test (fit), helicobacter pylori (hp) antigen test, ring finger protein 180 (rnf180) and septin9 gene methylation test, and investigation of risk factors, including past disease history, alcohol drinking history, smoking history, tea drinking history, family history of cancer, marital and reproductive status, and dietary habits. group two: the screening population will undergo investigation of risk factors, a fecal occult blood test (fit), and a stool test for helicobacter pylori (hp) antigen. if a stool occult blood test or h. pylori antigen is positive after testing, rnf180 and septin9 gene methylation testing will be scheduled. if the gene methylation test is positive, a colonoscopy will be scheduled. group one's control（spouse or sibling of group one);group two's control（spouse or sibling of group one): only the risk factors will be investigated, including previous disease history, drinking history, smoking history, drinking history, family history of malignant tumor, marriage and childbearing status, eating habits, etc. finally, 10 years follow-up will be conducted to observe the outcome

Eligibility criteria:
inclusion criteria: * 1. subjects were 45 to 70 years old when enrolled 2. willing and able to sign informed consent exclusion criteria: * 1. history of any type of malignancy 2. previous resection of esophagus, stomach or colorectal 3. received gastrointestinal endoscopy such as colonoscopy and gastroscopy in recent 5 years 4. have received fecal occult blood test and fecal dna test in the past 1 year. 5. contraindications to endoscopy. 6. warning symptoms of digestive tract tumors, including: 1. difficulty swallowing, choking or halting feeling when eating recently 2. recent esophageal foreign body sensation or swallowing pain 3. recent long-term loss of appetite and appetite 4. recent and prolonged symptoms of indigestion (including acid reflux, heartburn, abdominal grumbling, burping, nausea or premature satiety, etc.) 5. recent symptoms of abdominal mass, abdominal pain, vomiting or hematemesis 6. it was medically diagnosed as iron deficiency anemia 7. recent changes in hematochezia, black stool or stool character and frequency 8. recent symptoms of perianal discomfort (including soreness, itching, lumps, prolapse or other discomfort) 9. unexplained weight loss (more than 10% of base body weight) in the past 6 months step 7 get pregnant 8. there are other serious comorbiditions that reduce screening benefits (including severe lung disease, advanced kidney disease, advanced liver disease, severe heart failure, etc.)
a study evaluating the impact of an educational program (edu-mici) on patients with inflammatory bowel disease

Conditions: Crohn's Disease; Ulcerative Colitis

Summary: this study has the objective to demonstrate that an education program could have a significant impact on inflammatory bowel disease (ibd) patient's skills with regards to their disease.


Eligibility criteria:
inclusion criteria * male or female patients 18 -70 years of age * recent diagnosis (less than 6 months) of crohn's disease or ulcerative colitis or patients with an oldest pathology with a new flare, a complication and / or need to optimize medical therapy exclusion criteria * patients unable to understand and follow the program

Keywords: crohn's disease ulcerative colitis educational program inflammatory bowel disease psycho-pedagogic score ibd
physicians international coronary computed tomography angiography (ccta) utilization registry

Conditions: Coronary Artery Disease

Summary: this protocol describes an observational study whose goal is to collect de-identified coronary ct angiography (ccta) acquisition factors and interpretations (findings) from several hundred u.s. and international imaging facilities. the study uses an electronic data capture tool to collect de-identified ccta utilization parameters and clinical findings in order to create a multi-center registry. this registry will be used for scientific analysis and publication of pertinent medical trends such as ct utilization, radiation dose, and common cardiovascular findings. the registry will be used to determine areas of interest for future randomized controlled trials. all data will be collected with patient identifiers removed and in complete accordance with hipaa regulations. all data will be analyzed in aggregate, thus further minimizing the risk of patient confidentiality violations.


Eligibility criteria:
inclusion criteria: * adult participants who are able and willing to consent for themselves * patients scheduled for ccta examination exclusion criteria: * patients who did not complete the planned ct imaging procedure due to mechanical error of the ct machine.

Keywords: myocardial infarction
traditional chinese yijinjing exercise on hand dysfunction in rheumatoid arthritis patients

Conditions: Rheumatoid Arthritis; YiJinJing Exercise; Hand Function; Randomized Controlled Trial

Summary: this study is a single-blinded, randomized, parallel controlled trial.the purpose of this experiment is to confirm how "yijinjing" treatment affects hand function, handgrip strength, pain, morning stiffness, and mood disorder in ra patients compared to routine care.

to compare the efficacy of traditional chinese exercise yijinjing and routine care on hand dysfunction,which is the clinical challenge in rheumatoid arthritis (ra), a single- centre,single-blinded, randomized controlled trial will be conducted. sixty-six ra patients will be randomly allocated (1:1) to treatment with yijinjing exercise or routine care. the primary outcome is a 10% improvement in the michigan hand outcomes questionnaire (mhq) at week 12.

Eligibility criteria:
inclusion criteria: 1. meet the ra criteria by the american college of rheumatology(acr)/the european league against rheumatism(eular) in 2010 or the acr in 1987 2. between the ages of 18 and 65, regardless of gender 3. das28≤3.2 4. joint function in grades i to ii or x-ray in stages i to ii 5. no use or maintenance of a stable dose of dmards, biological agents, or hormones within 4 weeks prior to screening 6. wrist joints or finger joints (mcp, pip) were swollen or painful 7. tested for hand dysfunction by a professional rheumatologist 8. volunteer to participate exclusion criteria: 1. yijinjing exercise experience within the last 3 months 2. severe joint deformity (including subluxation and severe ulnar deviation) and joint ankylosis 3. other diseases affecting limb function such as trauma, fractures, infections, tumors, congenital malformations 4. present with complication diseases such as serious cardiovascular, brain, liver, lung, kidney, and hematopoietic system diseases 5. a moderate or severe cognitive impairment that unable to cooperate with the treatment 6. unwilling to join
resistance training and injection treatment for achilles enthesopathy

Conditions: Achilles Entesopathy

Summary: achilles enthesopathy is a common and often long-lasting injury among exercising individuals. very little is known regarding the effect of different treatment strategies. the purpose of the study is to evaluate two treatment strategies for achilles enthesopathy: resistance training and restricted loading + corticosteroid injection compared to resistance training and restricted loading + local anesthesia injection. 50 patients with achilles enthesopathy are randomly assigned to the two treatment groups in this double blinded rct.

achilles enthesopathy is a common and often long-lasting injury among exercising individuals. symptoms are pain and swelling at the calcaneal insertion of the achilles tendon during and after exercise. achilles entesopathy has not been thoroughly investigated and consequently, very little is known regarding the effect of different treatment strategies. the purpose of the study is to evaluate two treatment strategies for achilles enthesopathy: resistance training and restricted loading + corticosteroid injection compared to resistance training and restricted loading + local anesthesia injection. it is hypothesized that treatment that includes corticosteroid injection is more effective than treatment that includes injection with local anaesthesia. 50 patients with achilles enthesopathy are randomly assigned to the two treatment groups in this double blinded rct.

Eligibility criteria:
inclusion criteria: * pain from the achilles tendon insertion/heel for at least 3 months * achilles entesopathy verified by ultrasound * between 18 and 65 years of age exclusion criteria: * prior surgery in the leg with the exception of knee arthroscopy * known medial conditions including diabetes or rheumatologic diseases * taking pain medication regularly * injection therapy for treatment of achilles entesopathy within the last 6 months
superficial and cutaneous fungal infections among drug-users in northeast region of iran

Conditions: Skin and Subcutaneous Tissue Fungal Infections

Summary: the purpose of this study was about survey of prevalence of fungal infections among drug users referring to methadone wards of hospitals in northeast region of iran

there were two groups with overall members of 1436. statistically, the investigators have used "likelihood ratio " and " exact's fisher" tests.

Eligibility criteria:
inclusion criteria: * suspected fungal lesions exclusion criteria: * non use of local or edible anti-fungal drugs and not taking bath within the last 48 hours of testing
sifi vs fnb local anesthesia for hip fracture surgeries

Conditions: Hip Fractures; Surgery; Anesthesia, Local

Summary: the goal of this clinical trial is to compare two commonly used local/regional anesthesia techniques in adults patients undergoing hip fracture surgery. the main question\[s\] it aims to answer are: • the impact of both interventions on patient level of pain. • impact on postoperative analgesics administered participants will be randomly assigned to one of two local/regional anesthesia techniques, either femoral nerve block (fnb) or suprainguinal fascia iliaca block (sifi). both techniques are the usual practice at the hospital, and we are not aiming to experiment on new anesthesia technique in this study.

hip fracture in the elderly is an increasingly common problem worldwide. nearly all patients with a hip fracture undergo surgery. patients with hip fractures often have significant pain, particularly with movement, and surgical fixation is associated with significant pain. the treatment of pain with the use of a multimodal analgesic regimen is a major priority for elderly patients with hip fractures. these patients are often frail and have multiple medical comorbidities. hence the use of non-steroidal anti-inflammatories drugs and systemic opioids may be contraindicated or complicated by adverse effects. regional anesthesia techniques including femoral nerve blocks (fnb) and fascia iliaca compartment blocks (ficb) are frequently utilized as part of multimodal analgesia due to their relative lack of side-effects. femoral nerve blockade and suprainguinal fascia iliaca (sifi) blockade have been described for this indication. several studies have investigated the analgesic efficacy of the sifi block after total hip arthroplasty. however, randomized controlled trials on the analgesic efficacy of the sifi block for pain after hip fracture surgery are not plentiful and subject to methodological concerns. objectives: the primary objective is to test the hypothesis that in patients undergoing hip fracture surgery, suprainguinal fascia iliaca block is associated with improved pain scores and a reduction in opioid utilization when compared with femoral nerve block. secondary objectives will be to compare time to mobilization, time to readiness for discharge and complications associated with both nerve block techniques.

Eligibility criteria:
inclusion criteria: * age 18 or greater * having hip fracture surgery at the university of alberta hospital * suitable for multimodal analgesia including a peripheral nerve block exclusion criteria: * contraindication to a nerve block technique * refuses consent for a nerve block technique
clinical trial of blenderized tube feeds varying in viscosity

Conditions: Feeding Disorders

Summary: the investigators are conducting a 16 week multiple cross-over study (n-of-1 trial) comparing two blenderized tube feeds varying in viscosity in 40 children.


Eligibility criteria:
inclusion criteria: * age \> 1 year * \>90% of total calories via g-tube for \> 6 months * g-tube diameter ≥ 14 french * moderate severity of upper gi symptoms of nausea, bloating, postprandial fullness and early satiety defined as gastroparesis cardinal symptom index-daily diary (gcsi-dd) composite score \> 2 * anticipated stable gi-related medications for the duration of the study. exclusion criteria: * cystic fibrosis, primary ciliary dyskinesia, interstitial lung disease, bronchiolitis obliterans, or lung transplant * untreated malabsorptive intestinal disease (e.g. crohn's disease, celiac disease) * nissen fundoplication * use of non-standard enteral formulas (e.g. ketogenic formulas) for the management of metabolic, endocrine or neurologic rare diseases * allergy or intolerance to any component of the study diet * inability to tolerate bolus gastric feeds.
double-blind, double-dummy, 2-period crossover of a 20-minute versus a 4-hour iv of moa-728 in stable methadone subjects

Conditions: Constipation

Summary: moa-728, an investigational drug, is currently being studied for the relief of constipation associated with postoperative ileus and treatment of opioid induced constipation in patients receiving palliative care. this study will further investigate the iv formulation of moa-728 comparing pk/pd time points for a 20-minute versus a 4-hour infusion.


Eligibility criteria:
inclusion criteria: * generally healthy men and nonlactating, nonpregnant women age 18 to 65 years with bmi of 18.0 to 35.0 kg/m2 * must have been receiving methadone treatment of greater than or equal to 30 mg/day for at least one month and a positive drug screen for methadone * high probability for compliance with and completion of the study exclusion criteria: * significant cardiovascular, hepatic, renal , respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease. presence or history of any disorder that may prevent the successful completion of the study. any surgical or medical condition that my interfere with the distribution, metabolism or excretion of the test article. * acute disease state, family history of long qt syndrome and/or sudden cardiac death, allergy to opioids or drugs. use of any investigational or prescription drugs within 30 days, any otc drugs including herbal supplements within 14 days and drugs required to maintain regulation of bowel movements 48 hours before study day 1. * history of alcoholism within 1 month before study day 1, admitted alcohol abuse, or consumption of more than 2 standard units of alcohol per day.

Keywords: opioids chronic pain